UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 15 von 1767
Datensatz exportieren als...
BibTeX
Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin
Cancer, 2017-02, Vol.123 (3), p.390-400
Packiam, Vignesh T.
Johnson, Scott C.
Steinberg, Gary D.
2017
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Packiam, Vignesh T.
Johnson, Scott C.
Steinberg, Gary D.
Titel
Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin
Ist Teil von
Cancer, 2017-02, Vol.123 (3), p.390-400
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2017
Quelle
MEDLINE
Beschreibungen/Notizen
An unmet need exists for patients with high‐risk non–muscle‐invasive bladder cancer for whom bacille Calmette‐Guérin (BCG) has failed and who seek further bladder‐sparing approaches. This shortcoming poses difficult management dilemmas. This review explores previously investigated first‐line intravesical therapies and discusses emerging second‐line treatments for the heterogeneous group of patients for whom BCG has failed. The myriad of recently published and ongoing trials assessing novel salvage intravesical treatments offer promise to patients who both seek an effective cure and want to avoid radical surgery. However, these trials must carefully be contextualized by specific patient, tumor, and recurrence characteristics. As data continue to accumulate, there will potentially be a role for these agents as second‐line or even first‐line intravesical therapies. Cancer 2017;123:390–400. © 2016 American Cancer Society. An unmet need continues to exist for patients with high‐risk non–muscle‐invasive bladder cancer for whom Bacille Calmette‐Guérin has failed and who seek further bladder‐sparing approaches. This review explores the role of emerging intravesical therapies.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.30392
Titel-ID: cdi_proquest_miscellaneous_1868316804
Format
–
Schlagworte
Administration, Intravesical
,
bacille Calmette‐Guérin (BCG)
,
Bacillus Calmette-Guerin vaccine
,
BCG
,
BCG Vaccine - adverse effects
,
BCG Vaccine - therapeutic use
,
Bladder
,
Bladder cancer
,
bladder‐sparing
,
Cancer
,
chemotherapy
,
Clinical trials
,
Disease Management
,
Female
,
Health risks
,
Humans
,
Immunotherapy
,
intravesical
,
Invasiveness
,
Neoplasm Invasiveness - genetics
,
Neoplasm Invasiveness - immunology
,
Neoplasm Recurrence, Local - drug therapy
,
Neoplasm Recurrence, Local - immunology
,
Neoplasm Recurrence, Local - pathology
,
non–muscle‐invasive bladder cancer
,
Oncology
,
Patients
,
Salvage
,
Salvage Therapy - methods
,
Surgery
,
Treatment Failure
,
Urinary bladder
,
Urinary Bladder Neoplasms - drug therapy
,
Urinary Bladder Neoplasms - immunology
,
Urinary Bladder Neoplasms - pathology
,
urothelial neoplasms
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX